en · de · es · fr · pt
methods-notes.peptides4088.com › Info › Identity And Physical Form — Reference Sheet

Identity And Physical Form — Reference Sheet

By Editorial Desk · published 2025-10-19 · last reviewed 2025-11-13 · Info

If you have been reading about trifluoroacetate and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Physical Form

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Tb-500 at a glance

PropertyValueNotes
Molecular mass≈889 Da for the 7-residue fragmentFull-length thymosin beta-4 is ≈4.9 kDa; catalogs differ
AppearanceWhite to off-white powderHygroscopic; weight shifts with residual moisture
Solubility classFreely soluble in waterAlso dissolves in aqueous buffers; poorly soluble in nonpolar solvents
Typical storage temperature−20 °C, desiccated, protected from lightOnce rehydrated, short-term holding at 2-8 °C
Typical analytical methodReversed-phase HPLC with mass spectrometryPurity by UV absorbance; identity by ESI-MS or MALDI-TOF

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Related pages on this site

Thymosin Beta-4 Fragment Identity

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Detection, Stability, and Regulatory Status

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

Notes from published material

==== March ==== On 13 March, the Syrian government forces launched attacks toward Suwayda, Syrian government forces in Kharbat Samar attacked residents in the city of Ara. On 19 March, clashes erupted between Syrian government forces and local defense units, including the Syrian National Guard, on multiple fronts around Suwayda, encompassing Tal Hadid and villages such as Walgha and Mansoura, and involving heavy and medium weaponry. A day later, Israeli airstrikes targeted several positions of Syrian government forces at Izraa in Daraa Governorate, including command and control centres, supply depots, and facilities held by the 40th Battalion of the Syrian Army, in retaliation to the escalation of hostilities. On 25 March, a National Guard member was injured during clashes in the city of Era, in southern Suwayda.

In May 2016, Theranos announced that it had voided two years of results from its Edison device. The company announced that about 1% of test results had been voided or corrected from its proprietary machines in June 2016. Within two weeks, Walgreens formally terminated its partnership with Theranos and would close all remaining Theranos wellness centers. In August 2016, the company withdrew its request for emergency clearance of a Zika virus blood test after a lack of essential safeguards during the testing process was found by federal inspectors. Theranos announced that it would close its laboratory operations and wellness centers and lay off about 40% of its workforce to work on miniature medical testing machines in October 2016. In January 2017, Theranos announced that it had laid off a further 41% of its workforce, or approximately 155 people, and closed the last remaining blood-testing facility after the lab failed a second major U.S. regulatory inspection. Also that month, the company faced lawsuits from several different entities including Walgreens and Arizona Attorney General Mark Brnovich. In April 2017, lawyers for Partner Investments LP and two other funds, with combined stakes totaling more than $96 million in Theranos preferred shares, charged that Theranos had threatened to seek bankruptcy protection if the investors did not agree to accept additional stock equity in lieu of litigation. Theranos officials said the funds had mischaracterized the exchange offer, which was discussed before the suit was filed.

==== Recursive deconvolution ==== The method is made understandable by the figure. A 27-member peptide library is synthesized from three amino acids. After the first (A) and second (B) cycles samples are set aside before mixing them. The products of the third cycle (C) are cleaved down before mixing, and are then tested for activity. Suppose the group labeled by + sign is active. All members have the red amino acid at the last coupling position (CP). Consequently, the active member also has the red amino acid at the last CP. Then the red amino acid is coupled to the three samples set aside after the second cycle (B) to get samples D. After cleaving, the three E samples are formed. If, after testing, the sample marked by + is the active one, it shows that the blue amino acid occupies the second CP in the active component. Then the blue, then the red, amino acid is coupled to the three A samples (F) and tested again after cleaving (G). If the + component proves to be active, the sequence of the active component is determined and shown in H.

Though no Tyrannosaurus scleral ring has been found, Kenneth Carpenter estimated its size based on that of Gorgosaurus. The inferred scleral ring for the Stan specimen is ~7 cm (2.8 in) in diameter with an internal aperture diameter of ~3.5 cm (1.4 in). Based on eye proportions in living reptiles, this implies a pupil diameter of about 2.5 cm (0.98 in), an iris diameter about that of the scleral ring, and an eyeball diameter of 11–12 cm (4.3–4.7 in). Carpenter also estimated an eyeball depth of ~7.7–9.6 cm (3.0–3.8 in). Based on these calculations, the f-number for Stan's eye is 3–3.8; since diurnal animals have f-numbers of 2.1 or higher, this would indicate that Tyrannosaurus had poor low-light vision and hunted during the day. Tyrannosaurus had very large olfactory bulbs and olfactory nerves relative to their brain size, the organs responsible for a heightened sense of smell. This suggests that the sense of smell was highly developed, and implies that tyrannosaurs could detect carcasses by scent alone across great distances. The sense of smell in tyrannosaurs may have been comparable to modern vultures, which use scent to track carcasses for scavenging. Research on the olfactory bulbs has shown that T. rex had the most highly developed sense of smell of 21 sampled non-avian dinosaur species.

Sources: en.wikipedia.org

Further detail

After fascism came to power with the March on Rome on 28 October 1922, a centralized dictatorial regime began in the southern region, strengthened after the assassination of socialist deputy Giacomo Matteotti in 1924 and formalized with the Leggi fascistissime of 1925–1926, which outlawed all political parties except the fascist party, censored the press, and banned trade unions and strikes. In addition, mayoral elections were abolished, replaced by podestà, appointed by the prefect, with absolute powers in political and economic management. During this period, the most representative Calabrian political personality was Michele Bianchi, a native of Belmonte Calabro, who was a close associate of Mussolini and quadrumviral of the 1922 March on Rome, in addition to holding the posts of deputy, undersecretary at the Ministry of the Interior and, finally, minister of Public Works. In this capacity, which he held until his death in 1930, he had a number of infrastructures built in Calabria, such as the Camigliatello Silano ski resort (initially called Camigliatello Bianchi), as well as promoting public works in Cosenza while Tommaso Arnoni was mayor (1925–1934). In December 1924 a false rumor spread in Reggio Calabria that Benito Mussolini had resigned as Prime Minister because of the Matteotti affair, leading to joyous all-night celebrations. In the morning, the people learned that Mussolini was still prime minister. Several Fascist officials were dismissed for not suppressing the celebrations.

== History == Sam Chun Dang Pharm was established on December 29, 1943, to manufacture and sell pharmaceutical products. The company is widely recognized as the first Korean pharmaceutical company to manufacture eye drops. In 1985, SCD constructed a KGMP-certified factory within the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. In 2013, SCD acquired Optus Pharmaceuticals, at the time the leading domestic manufacturer of single-use ophthalmic eye drops. SCD received the European Union Good Manufacturing Practice certification from the UK MHRA in March 2015, and a further EU GMP certificate from Germany's BGV in April 2018, allowing the company to expand into international markets.

=== Fertility support === Progesterone is used for luteal support in assisted reproductive technology (ART) cycles such as in vitro fertilization (IVF). It is also used to correct luteal phase deficiency to prepare the endometrium for implantation in infertility therapy and is used to support early pregnancy.

Sources: en.wikipedia.org

Supporting material

=== Low blood calcium === 10% calcium gluconate solution (given intravenously) is the form of calcium most widely used in the treatment of acute and/or severe low blood calcium. Unless calcium gluconate is not available, calcium chloride is generally not recommended as a substitute. This is because the calcium chloride is more likely to cause tissue damage if the IV becomes dislodged during the infusion.

=== Management === The management of uterine prolapse may be conservative or surgical, depending on factors such as personal preference, symptom severity, and extent of prolapse. Additionally, management of existing medical conditions that can contribute to prolapse, such as chronic lung conditions or obesity, are important to prevent progression of uterine prolapse and reduce symptom burden.

== Montagnard influence == The working class was especially hurt by a hail storm which damaged grain crops in 1788, which caused bread prices to skyrocket. While the peasants of rural France could sustain themselves with their farms, and the wealthy aristocracy could still afford bread, the urban workers of France, the group that comprised the sans-culottes, suffered. In the city, the division grew between the sans-culottes and these wealthy aristocrats; the former had a particular hostility "towards those with large private incomes." The faction known as the Montagnards expressed concern for the working classes of France. When the National Convention met to discuss the fate of the former king Louis XVI in 1792, the sans-culottes vehemently opposed a proper trial, instead opting for an immediate execution. The moderate Girondin faction voted for a trial, but the radical Montagnards sided with the sans-culottes, deeming that a trial was not necessary, and won with a slim majority. Louis XVI was executed on January 21, 1793. The demands of the sans-culottes did not stop with the execution of the King, and the Montagnards worked hard to fulfil their mounting orders. This increased pressure from the radical masses exacerbated the ideological split between the Montagnards and the Girondins, and tensions began to grow within the convention. Eventually, by May 1793, the Montagnards worked with the National Guard—which was, at this time, mostly sans-culottes—to depose many of the Girondin deputies.

Rhodiola is a genus of perennial plants in the family Crassulaceae that resemble Sedum and other members of the family. Like sedums, Rhodiola species are often called stonecrops. Some authors merge Rhodiola into Sedum. Rhodiola species grow in high-altitude and other cold regions of the Northern Hemisphere. Plants of the World Online gives the number of accepted species as 74, the Angiosperm Phylogeny Website gives it as 90, and the Flora of China gives it as about 90, with 55 in China and 16 endemic there. Flora of North America lists only three species in the United States and Canada.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Why do descriptions of this material differ so much?

The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.

What does a stated purity percentage measure?

Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

Network